EASME

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

eLive Ecosystem specializes in developing innovative solutions aimed at preventing long-term diseases through advanced technology. The company has created an artificial intelligence-based medical device specifically designed for the self-measurement of sleep apnea, addressing diagnostic gaps and enhancing treatment monitoring. By integrating medicine, genomics, and advanced sensor technology, eLive aims to alleviate the pressures on healthcare systems caused by demographic changes and aging populations. Their platform focuses on enabling healthcare professionals to efficiently and cost-effectively manage disease prevention and treatment, ultimately improving patient outcomes on a global scale.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

CardiacSense Ltd. is an Israeli company founded in 2012, specializing in the development of medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company offers FDA and CE certified medical watches and wristbands that provide continuous, long-term, non-invasive monitoring of vital signs, including heart rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced photoplethysmography (PPG) technology, CardiacSense's devices enable real-time diagnostics for various medical conditions, including atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD), heart failure, sleep apnea, and infections such as COVID-19. By focusing on affordability and comfort, CardiacSense aims to enhance patient care and preventative measures within the healthcare industry.

CMI NOV is a healthcare company based in Monistrol sur Loire, France, specializing in the design, development, and manufacturing of medical devices for surgical applications. Founded in 2013, the company focuses on various medical fields, including cardiology, visceral surgery, gynecology, urology, and bariatrics. Notably, CMI NOV offers solutions for mitral valve repair, enhancing surgical procedures during open heart surgeries. Through its innovative products, the company aims to improve patient outcomes and support healthcare professionals in delivering high-quality surgical care.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

Stokhos B.V., based in Amsterdam, Netherlands, develops software aimed at optimizing the deployment of emergency vehicles, particularly ambulances. Initially conceived as a scientific mathematical project named REPRO, the company's flagship product, known as seconds, utilizes advanced algorithms to provide real-time coverage advice to emergency dispatch centers. By analyzing factors such as population density, historical incident data, and road networks, Stokhos's platform enables dispatchers to determine the optimal placement of ambulances, ensuring that they can respond swiftly to emergencies within required timeframes. The team at Stokhos is deeply committed to enhancing public safety and has a strong connection to the medical emergency sector, with all members holding valid first aid certifications.

BioSpeedia develops and manufactures a vitro diagnostics rapid test kits and ELISA kits for medical professionals.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

ControlNano is a spin-off company leaded by a group of professionals with high expertise in the field of health risk assessment related to the exposure of nanoparticles in industrial facilities and urban environments. They design and manufacture highly reliable and robust devices to provide accurate information on the concentration levels of nanoparticles and respirable dust in air.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Healthplus.ai specializes in a surgical patient risk management platform that leverages electronic health record data to enhance surgical care. By utilizing AI and machine learning algorithms, the platform integrates seamlessly with existing EHR workflows to predict potential complications following surgery. This proactive approach allows healthcare professionals to identify early warnings of post-surgery infections and other significant risks, thereby improving patient outcomes and reducing overall costs. Healthplus.ai's technology empowers clinical staff to deliver tailored support to patients, ultimately fostering a more effective and efficient surgical care environment.

Hedia is a health application designed to assist individuals with type 1 and type 2 diabetes by leveraging artificial intelligence. The application analyzes the user's patterns and habits, providing personalized insulin recommendations based on their carbohydrate intake and exercise levels. By facilitating better insulin management, Hedia aims to enhance the everyday lives of people living with diabetes, making it easier for them to control and monitor their condition effectively.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

Pre Diagnostics is a Norwegian diagnostic company specializing in the development of innovative in-vitro diagnostic (IVD) products aimed at the early detection of diseases, particularly neurodegenerative conditions like Alzheimer’s disease. The company leverages a proprietary approach based on the premise that specific diseases trigger unique systemic responses in macrophages, which can be measured through blood samples. By focusing on intracellular measurements of disease-specific biomarkers within blood cells, Pre Diagnostics aims to provide healthcare professionals with actionable insights for early diagnosis. Their commitment to creating patient-friendly solutions positions them as a potential leader in the field of early Alzheimer’s detection, utilizing established technologies to develop their biomarker products.

Medfield Diagnostics AB, founded in 2005 by Mikael Persson and Andreas Fhager, specializes in the development and commercialization of diagnostic instruments utilizing microwave technology. The company focuses on advancing stroke diagnostics through its innovative products, including Strokefinder and Impending Applications. By leveraging promising research conducted at Chalmers University of Technology, Medfield Diagnostics aims to enhance the accuracy and efficiency of stroke detection and management.

MyoSwiss AG, founded in 2017 and based in Zurich, Switzerland, specializes in medical technology aimed at enhancing mobility for individuals with muscle weakness. The company develops innovative products such as the Myofit and Myosuit, which serve as advanced training devices for rehabilitation and physiotherapy. These devices are designed to improve the quality of life for users by providing an additional layer of muscle support, thereby enabling them to regain their mobility and independence. MyoSwiss also offers personalized training plans, intensive activity-based training, and performance tracking to enhance the effectiveness of its solutions, helping individuals with mobility impairments realize their potential for physical activity.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

The WLTS laboratory is organized to take samples of asbestos (air and material) and to analyze the samples taken.

Waterscope is a not-for-profit impact-defined company based in Cambridge. Waterscope is a Cambridge University spin-out developing easy-to-use, rapid water testing microscopes capable of identifying bacterial presence in drinking water. Their bacterial imaging device can identify specific bacterial micro-colonies in less than 6 hours, four times faster than current gold-standard portable systems. Their system is automated, not requiring significant user training. Using image recognition software, bacterial colonies can be automatically identified and counted. Once data is collected the bacterial imaging device will automatically upload and disseminate results for mapping or intervention. THeir novel bacterial cartridge simplifies bacterial testing eliminating the need for a central lab and significant user training.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Clover Bioanalytical is a bioinformatics company that specializes in data processing for bioanalytical chemistry and clinical diagnostics applications, particularly utilizing mass spectrometry. Founded by a team of Ph.D. graduates with expertise in both business and research, the company focuses on developing advanced software and statistical analysis tools for the biomedical field. Clover’s capabilities extend beyond mass spectrometry to include medical image processing and both univariate and multivariate statistical analysis, addressing the challenges posed by Big Data. The company emphasizes a customer-oriented approach, aligning its solutions with the specific goals and scalability needs of its clients. By leveraging artificial intelligence, Clover aims to enhance the rapid identification of microorganisms, positioning itself as a key partner for hospitals, research institutions, and biotechnology companies in tackling significant scientific questions.

SensoGenic, Inc. develops innovative diagnostic biosensors specifically designed to detect food allergens. Founded in 2016 and based in Ness Ziona, Israel, the company offers portable, handheld analyzers that connect to a mobile application, allowing users to identify allergens without physical contact. This technology provides critical information for individuals with food allergies, enabling them to dine out safely and avoid allergic reactions. SensoGenic emphasizes understanding user needs to enhance the functionality and usability of its products, positioning itself as a leader in allergen detection solutions.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, aiming to alleviate pain and stress in pre-term infants while enhancing parent-child bonding. The company specializes in the design, development, and manufacturing of innovative products for Neonatal Intensive Care Units (NICUs) in hospitals. One of its key offerings is a wireless health monitoring device that tracks critical health metrics such as breathing, heart rate, temperature, and electrocardiogram (ECG) without the discomfort associated with traditional adhesive electrodes. This device facilitates maximum skin-to-skin contact between infants and their parents, allowing for effective monitoring of the baby's health while minimizing pain and skin irritation.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

DermoSafe is a Swiss company based in Cheseaux, founded in November 2012 by Philippe Held. The company specializes in innovative medical devices designed for the early detection and management of melanoma. Its primary product captures high-definition dermoscopic images of moles and pigmented lesions, allowing general practitioners to enter patient data and refer images to dermatology specialists via a secure web application. This platform facilitates the analysis of images, enabling specialists to provide electronic reports that assist in the early identification of melanoma and the management of treatment. DermoSafe's approach enhances collaboration between primary care practitioners, patients, and specialists, ultimately aiming to improve outcomes in melanoma care.

PlanDomino specializes in digital lab scheduling software designed to enhance the efficiency of resource allocation and manage testing workflows in laboratories. By utilizing a fully digitized system, PlanDomino enables significant productivity improvements, with potential savings exceeding 50 percent, while reducing lead times and eliminating the need for extensive training or costly consultants. The platform incorporates visual management technology to connect laboratory operations with supply chains, fostering collaboration among different departments. This integrated approach enhances the allocation of work for analysts and provides comprehensive visibility of samples as they progress through the lab, ultimately streamlining processes and boosting overall productivity.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

Rithmi is a privately held company focused on heart health and stroke prevention through innovative arrhythmia detection technologies. The company has developed a device that records data and detects arrhythmias in real time by measuring the intensity of light reflected on the skin's surface, creating a waveform of heart pulses. This technology offers a level of accuracy comparable to an electrocardiogram (ECG), making it a significant advancement in the diagnosis of atrial fibrillation. After successful pilot tests of its prototype, Rithmi is poised to expand into new markets in Europe, demonstrating strong potential for rapid growth and a commitment to enhancing patient care through its unique approach to Computational Predictive Care.

LuxAI is a startup that focuses on developing socially assistive robots aimed at enhancing education, healthcare, and entertainment. Originating as a spin-off from the University of Luxembourg, the company leverages advancements in artificial intelligence and robot therapy to create robots that assist individuals, particularly those with neurodevelopmental disorders such as autism. Their robots are designed to engage users through diverse facial expressions, body gestures, and behaviors, making evidence-based educational methods more accessible. LuxAI's mission is to provide economical and user-friendly robotic solutions, enabling teachers, therapists, and caregivers to integrate these advanced tools into their daily practices, ultimately improving health outcomes and educational experiences for individuals in need.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

DART Diagnostics is a diagnostic company focused on enhancing diagnostic assays through innovative technologies. Founded by scientists who frequently encounter challenges in detection, the company aims to address the widespread need for improved and timely results across various sectors, including water analysis, food safety, and clinical diagnostics. DART Diagnostics specializes in developing bio-inspired polymers for nanotechnology, which amplify signals from immunoassays. This advancement allows healthcare professionals to achieve more efficient results, ultimately saving time, reducing costs, and potentially safeguarding patient lives.

Neurosteer has developed a medical-grade wearable device and cloud-based system aimed at the early detection and treatment of neurological disorders. The solution features an adhesive forehead strip linked to a pocket-sized sensor that wirelessly transmits brain activity data to the cloud for processing. Utilizing advanced algorithms, the system decomposes a single EEG channel into over 100 individual components for real-time analysis, which is displayed on a web-based dashboard. Neurosteer's primary focus is on identifying early signs of conditions such as Parkinson's, Alzheimer's, dementia, and epilepsy. This innovative approach allows for more affordable screening, continuous monitoring of patients, and enhanced neurostimulation and drug selection, ultimately improving the treatment outcomes for neurological disorders and optimizing clinical trials.

Menutech is a B2B SaaS company focused on transforming the foodservice technology sector through AI-driven menu planning personalization. Its platform caters to food and beverage managers, dieticians, and nursing staff by automating the creation of meal plans tailored to individual dietary needs. This innovative solution significantly reduces the time required to prepare personalized meal plans by up to 90%, thereby minimizing health risks and lowering procurement costs for hospitals, senior homes, and hospitality businesses. Menutech's software also ensures safe menu planning by coordinating ingredient lists with allergen information and detecting potential allergens in recipes, allowing clients to manage daily or special menus effectively and safely.

Invent Medical's mission is helping people. New technology will constantly disrupt and change the medical field. They apply digital technologies to invent, develop and design a new generation of custom-made orthotic & prosthetic products so patients can experience better treatment outcomes.

LifeTag is a Portuguese technology startup that specializes in the research and development of non-invasive diagnostic technologies aimed at evaluating metabolism and diagnosing various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. The company has developed a diagnostic marker that facilitates non-invasive health monitoring, particularly focusing on intestinal permeability to enhance the accuracy of chronic metabolic disease diagnoses. By providing healthcare professionals with effective tools to assess patients without causing discomfort or side effects, LifeTag aims to improve health outcomes and streamline the diagnostic process.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.

Rqmicro is a Swiss company based in Zurich that specializes in pathogen separation and detection technology. Founded in 2013, it focuses on providing rapid microbial assessments for water and food safety. The company has developed proprietary reagents and instruments that deliver accurate results in less than one hour, allowing for quick detection of dangerous water and foodborne pathogens. This technology enables clients to obtain quantitative data on contamination levels, thereby enhancing overall safety in food and water supplies.

Avia-GIS NV is a Belgian SME founded in 2001 that specializes in spatial risk mapping and modelling as a basis for the development of tailored spatial decision support systems applied to public-, animal- and crop health and integrated pest management. Their company has a unique market position. Only few companies operate in their domain and developed such close contacts with the industrial, institutional and academic world. They have offices in Belgium, South Africa and Guadeloupe, and are active in more than 50 countries.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

Corti is an artificial intelligence platform focused on improving medical triaging through advanced voice-based technology. It enhances patient interactions by analyzing interviews and preparing case files prior to consultations. By utilizing proprietary speech recognition and natural language processing, Corti helps healthcare providers understand patient situations more effectively. The platform also suggests relevant questions to ask during consultations, aiming to reduce errors and increase the accuracy of clinical decisions. Trusted by leading healthcare providers, Corti integrates seamlessly into existing workflows, ultimately striving to save more lives by enabling faster and more precise decision-making in medical care.

Symptoma GmbH, founded in 2007 and based in Austria, has developed an innovative medical search engine that aids in the diagnosis of diseases by allowing physicians to search for information based on patients' symptoms. The platform enables healthcare professionals to access a comprehensive database that includes symptoms, lab results, and potential complications associated with various conditions. By filtering search results according to factors such as age, location, and gender, Symptoma assists in identifying diseases that may be misdiagnosed or diagnosed too late. This tool not only enhances the accuracy of medical diagnoses but also plays a crucial role in improving patient outcomes by facilitating timely and appropriate medical interventions.

GenomSys SA, established in 2016 and headquartered in Lausanne, Switzerland, specializes in developing tools and applications for processing and sharing DNA data. The company's core offering is a modular, robust, and certified platform that efficiently processes, stores, and shares genomic data. This platform, based on the ISO/IEC 23092 genomic standard, enables secure storage of individual DNA data on personal devices and facilitates sharing with practitioners for various applications, including diagnostics, pharmacogenomics, personalized treatments, and dietary recommendations. GenomSys' solutions are designed to be cheaper, faster, interoperable, and regulatory-conscious, accelerating the widespread adoption of personalized genomics.

GlyCardial Diagnostics S.L., established in 2017 and based in Barcelona, Spain, is a biotechnology company that focuses on developing innovative diagnostic solutions for cardiovascular health. The company specializes in a point-of-care device designed to detect abnormal levels of the Apo J-Glyc protein in the blood, which serves as a biomarker for the early diagnosis of cardiac ischemia. This technology aims to identify patients at risk of recurrent cardiovascular events and facilitate timely healthcare decisions to prevent irreversible myocardial damage and heart failure. As a spin-off from the Catalan Institute of Cardiovascular Sciences and the Spanish National Research Council, GlyCardial Diagnostics addresses critical unmet medical needs in the field of cardiology.

Grundium Ltd, established in 2015 and headquartered in Tampere, Finland, specializes in imaging and multi-camera solutions. The company caters to diverse industries such as transportation, biotechnology, and professional imaging, offering end-to-end solutions that include hardware, software, and user services. Grundium's core expertise lies in providing high-quality, portable digital microscope scanners designed for live telepathology consultations, enabling real-time, high-resolution image transmission between surgeons and pathologists, regardless of location. This innovative technology enhances diagnostic pathology, expands its reach, and reduces costs. Additionally, Grundium offers multi-camera solutions for the transportation industry, capable of withstanding harsh environmental conditions, and provides imaging solutions for various other sectors.

Biomode is a Portuguese startup located in Caldas das Taipas that specializes in developing rapid and accurate molecular diagnostic tests for identifying pathogens within the food, environmental, and life sciences sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) technology, Biomode's diagnostic kits provide a streamlined approach that eliminates the need for DNA extraction or amplification, ensuring reliability in the presence of inhibitory compounds and focusing solely on viable bacterial cells. The company plans to launch its first product, Probe4Salmonella®, for detecting Salmonella in food samples, followed by additional kits for Listeria monocytogenes and E. coli O157:H7. In the clinical diagnostics realm, Biomode has developed Probe4Pylori®, which is designed for the rapid identification of clarithromycin-resistant Helicobacter pylori strains and is currently seeking investigational device exemption from the FDA to commence field trials. Founded by researchers from the universities of Minho and Porto, Biomode aims to enhance pathogen detection in both food safety and health diagnostics.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

Tarsio Medics is a company which specialises in investigating non-invasive methods to diagnose sleep disorders based on automatic image analysis Tarsio Medics has dedicated over 10 years of research in conjunction with the Pulmonology department of the Germans Trias i Pujol Hospital to create SleepWise. SleepWise is a system based on analysing the images recorded by a camera while a patient sleeps. SleepWise uses these images to perform an automatic OSAHS diagnosis and also to detect other sleep disorders.

Macro Array Diagnostics is a Vienna-based MedTech company. They develop, produce and distribute tests, instruments and software for allergy diagnostics and research applications. Their products allow flexible, reliable and affordable sensitization profiling of each patient. Their multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs.

BioProbe Diagnostics (BPD), established in 2017 as a spin-out from NUI Galway, focuses on commercializing proprietary nucleic acid diagnostics technologies for detecting microbial contaminants in environmental and industrial settings. The company has secured worldwide licenses for its innovative technologies, aimed at enhancing the safety and quality of water testing. BPD collaborates closely with NUI Galway to advance its technology from laboratory development to market readiness. The team, comprised of experienced scientists and business professionals, is currently preparing to launch its first product, Bio-Lp-1, which offers a new capability for testing Legionella bacteria, a pathogen associated with severe pneumonia. This novel testing solution aims to provide pathology centers with an effective and affordable alternative for identifying waterborne threats.

Glucostratus Ltd develops innovative solutions for remote monitoring of blood glucose levels, primarily targeting patients with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company provides a cloud-based platform that captures blood glucose data via mobile technology, enabling patients to share their results with healthcare providers. This system allows professionals to set personalized targets and receive automated alerts regarding any deviations, facilitating effective remote monitoring of insulin treatment. Additionally, Glucostratus offers a digital solution for diagnostic testing and generates comprehensive reports in accordance with treatment guidelines. Their services include a user-friendly IoT solution designed for elderly diabetics, ensuring accessibility for those with limited technological skills and addressing the growing needs of the home care sector.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

BluSense Diagnostics specializes in developing innovative blood testing devices aimed at diagnosing infectious diseases. The company's technology utilizes a nanotechnology biosensing method, allowing for accurate results from just a single drop of blood. This consumer-oriented device enables individuals to monitor and manage virus outbreaks effectively. By integrating advanced Scandinavian bioengineering with high-quality Taiwanese hardware and software engineering, BluSense has established a breakthrough diagnostics system that addresses the pressing need for efficient infectious disease testing.

Oncoscanner is an oncological probe for intra-operative identification of cancerous tissues during surgical treatment for breast cancer.

Tethis S.p.A. is an Italian company based in Milan that specializes in the development, manufacturing, and sale of in vitro diagnostic devices, particularly for fluorescent in situ hybridization (FISH) assays. Founded in 2004, Tethis operates within the bio- and nanotechnology sectors, offering a range of products, including a proprietary coated slide with microfluidic compartments, an automated slide staining system, and an instrument that facilitates key steps in the FISH protocol. The company's innovative diagnostic device enables the detection of circulating tumor cells through liquid biopsy, supporting early cancer diagnosis and personalized medicine. Tethis S.p.A. aims to improve clinical outcomes by providing tools for targeted therapy and monitoring minimal residual disease, thereby contributing to the advancement of healthcare solutions.

Refecor is a technology company that specializes in providing comprehensive design solutions for various industries, including healthcare, sports, and consumer electronics. They offer a wide range of services, from embedded software solutions to full production design, encompassing system engineering, antenna design, software design, and user interface design, among others. Refecor also provides testing, quality checks, and production support, enabling clients to manage their projects on a turnkey basis.

Scopio Labs Ltd., founded in 2015 and based in Tel Aviv, Israel, specializes in the development of advanced digital microscopes that utilize computational imaging technology. The company focuses on enhancing hematology diagnostics by providing tools that allow for high-resolution imaging of blood samples and bone marrow aspirates. Scopio Labs' solutions aim to improve the efficiency and accuracy of diagnosing blood-related diseases by enabling laboratories to analyze cell morphology at scale. Their offerings cater to various applications, including cancer screening, cytology, academic research, and drug discovery, thus unlocking actionable insights from complex datasets in clinical settings.

NovaGray is focused on creating a new generation of companion diagnostic tests designed to enhance radiation therapy planning. The company develops biomarker-based tests that evaluate patients' sensitivity to radiotherapy through a single blood sample. This approach allows healthcare practitioners to tailor treatment doses and session sequences based on individual patient profiles. By personalizing standard treatments according to patients' specific sensitivities, NovaGray aims to improve clinical outcomes while also reducing both complication and overall treatment costs.

Atana is a wastewater treatment solutions provider based in Bardon Hill, United Kingdom, with additional offices across the UK and Europe. The company's head office in Leicestershire houses various departments, including manufacturing, logistics, laboratory, engineering, and administrative support. Atana's technical sales team comprises experts in engineering, chemistry, and manufacturing, who provide specialized advice on effluent plant treatment design, servicing, and optimization. The company also offers volute dewatering solutions, coagulants, and flocculants. Staff members in technical sales support, marketing, compliance, and laboratory functions are well-versed in quality and environmental management systems, while health and safety is overseen by NEBOSH qualified personnel. Strategic alliances with key players in the wastewater treatment industry enhance Atana's ability to deliver comprehensive operative training and consultancy services.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

Mermaid Care is a medical Technology firm that provides leading technology, care systems and solutions in optimizing the Ventilation Management within the Intensive Care Unit and Anaesthesia segment. Founded in 2006, the company has envisioned to be globally recognized amongst Key Opinion Leaders and Commercial Partners.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

PixCell Medical Technologies specializes in the development, production, and marketing of portable medical diagnostic products designed for point of care testing. Utilizing its innovative Viscoelastic Focusing (VEF) technology, the company offers single-use cartridges that facilitate rapid, accurate, and straightforward blood sampling and analysis. The results from these tests are available within minutes and presented in an easily interpretable format. PixCell aims to enhance accessibility to medical testing, making procedures typically confined to laboratory settings more user-friendly and affordable for a broader audience.

Aureel is a company focused on enhancing physical activity through innovative spatial technology aimed at sports optimization. Their technology is designed to analyze and manage an individual's running pace and various training settings, thereby supporting athletes in improving their performance. Additionally, Aureel offers an application that allows users to track their records, making exercise more accessible and tailored to individual health levels and fitness goals. Through these advancements, Aureel aims to create a more effective and personalized workout experience that promotes overall health and physical conditioning.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Serosep is a manufacturer and a distributor of laboratory diagnostic solutions. Serosep Limited is founded in Limerick Ireland. Serosep begins life as distributor of laboratory diagnostic products. The manufacture of HistoPot®, Biopsy Fixation Solutions for Histopathology begins. Precision water chemistry reagents are launched. Development of EnterBio® faecal/stool pathogen test kit for bacteria begins.

HAWK Biosystems specializes in cancer diagnostics through a companion diagnostics platform that identifies post-translational modifications and protein-protein interactions in pathology samples. The platform quantifies these interactions in single-cell and fixed tissue samples, maintaining the integrity and heterogeneity of the tissue. This technology offers medical practitioners and pharmaceutical companies a novel approach to treatment decisions, particularly in cancer, inflammation, and immune disorders. HAWK Biosystems aims to enhance precision medicine by enabling targeted therapies that match patients with the treatments most likely to be effective, thereby improving patient outcomes, quality of life, and reducing overall drug costs. The company seeks to establish collaborative opportunities within the European health system to further its impact in the field.

Amolab's mission is to provide the world medical community with the first technological solution for the safe, automatic and non-invasive monitoring of labor. Amolab offers doctors an objective and reliable tool to assess fetal well-being during the transition from intrauterine to extrauterine life. Amolab's vision is to put science at the service of society for the development of non-invasive solutions aimed at improving the quality of life and making the global health system more effective and more sustainable. The goal of the company is to be a leading company in the field of technological innovation applied to the medical-health field.

Neola Medical AB is focused on advancing neonatal intensive care through its innovative device, NEOLA. This medical technology offers continuous monitoring of lung function and real-time alerts for life-threatening complications in preterm infants. By measuring changes in lung volume and oxygen gas concentration, NEOLA aims to enhance patient care, reduce the duration of intensive care stays, and improve overall health outcomes for vulnerable newborns. The company is rooted in Sweden's rich history of medical technology innovation, which has significantly contributed to advancements in healthcare.

Salumedia Labs is a developer of evidence-based digital therapeutics focused on enhancing adherence to healthy lifestyles and medical treatments. The company utilizes behavioral science, artificial intelligence, and digital engagement techniques to create products that empower patients and facilitate lifestyle changes. In 2021, Salumedia Labs was acquired by Adhera Health, Inc., furthering its mission to support individuals in their health journeys.

DiamLite specializes in the development and production of innovative permanent markers using micro and nano-sized fluorescent diamonds. The company employs a patented production method that ensures cost efficiency and high-quality standards, including purity and homogeneity. These fluorescent diamonds exhibit superior fluorescence characteristics, making them suitable for various applications in health and life sciences, particularly in in-vitro diagnosis and bio-imaging. By leveraging their advanced technology, DiamLite aims to provide an effective alternative to traditional optical probes and marking solutions.

optiQGain Ltd. specializes in developing advanced molecular level diagnostic and imaging systems utilizing Quantum-Optics techniques. Founded in 2011 and headquartered in Tal Shahar, Israel, the company offers innovative products such as the SRS Analyzer, which provides real-time, high-resolution analysis of combustion input and output materials, including natural gas and exhaust emissions. This technology is applicable across various sectors, including medicine, energy, and food storage, facilitating efficient monitoring and optimization of industrial processes. By enabling label-free detection of target molecules in under one second, optiQGain aims to transform clinical medicine through real-time bedside monitoring, allowing for early symptom detection and continuous treatment assessment. This approach has the potential to enhance patient outcomes while reducing healthcare costs.

NeuroPsyCAD provides clinicians with patient-personalized reports for early and accurate diagnoses of neuropsychiatric disorders. NeuroPsyCAD's analysis pipeline is automated, with a report being produced in a few hours since they receive the patient's data. Given the high sensitivity and specificity of our approach, subtle changes in brain structure and function can be detected early and accurately at the disease onset, enabling clinicians to diagnose and, thus, treat patients earlier and with more confidence. NeuroPsyCAD aims to replace the so far relatively subjective and metrics-independent practice of psychiatry and neurology with a more quantified, objective, accurate, and personalize one.

SDS Optic, based in Lublin, is an innovative biotech company that develops advanced diagnostic solutions aimed at improving cancer detection and treatment. The company operates at the intersection of biochemistry, engineering, and fiber optic technologies, creating methodologies for in-vivo cancer diagnosis with single-cell resolution. SDS Optic specializes in the pre-assembly of both hermetic and standard photoelectronics components, contributing to the efficiency and effectiveness of its diagnostic tools. By focusing on novel approaches in oncology, the company addresses the pressing needs of patients and healthcare providers, striving for quicker and less painful diagnostic processes.

Genomic Expression Inc., established in 2009 and headquartered in Beverly, Massachusetts, specializes in developing cancer diagnostics. The company's core technology, OneRNA, employs RNA sequencing to help healthcare professionals select the most effective drug treatments for their patients. By analyzing RNA, Genomic Expression aims to detect diseases, monitor health, and design next-generation cures, offering a paradigm shift in personalized medicine.

Tremitas is the developer of Tremipen®, a measuring device for Parkinson and other tremor diseases. The Tremipen® is a medical device that can be used by tremor patients themselves to safely and reliably measure the strength and frequency of the tremor. The Tremipen® is as easy to use as a clinical thermometer. It gives patients the feeling of control and provides physicians with objectively secured values ​​that can support diagnosis and therapy selection.

Glycobond specializes in the development and production of proprietary carbohydrate-binding reagents aimed at enhancing diagnostics for liver diseases and cancer. The company has created HepaCheC™, an ELISA-based assay that identifies abnormal and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein primarily produced in the liver. This innovative assay allows for analysis using simple blood samples, leveraging a patented fucose-binding protein known as Mono-F. Glycobond's approach has demonstrated promising results in monitoring patients at risk of developing hepatocellular carcinoma (HCC), offering a valuable tool for physicians in diagnosing and managing liver conditions.

GeneFirst is a molecular diagnostics company specializing in infectious disease, cancer diagnostics, and personalized medicine. The company develops sensitive and affordable diagnostic technologies and products aimed at researchers, clinicians, and pharmaceutical companies. GeneFirst's innovative platform allows for the simultaneous detection of multiple targets in a single reaction, enhancing the accuracy of diagnoses and facilitating the delivery of safe and effective treatments. By providing easy-to-use diagnostic solutions, GeneFirst aims to improve patient outcomes and support advancements in medical science.

Rqmicro is a Swiss company based in Zurich that specializes in pathogen separation and detection technology. Founded in 2013, it focuses on providing rapid microbial assessments for water and food safety. The company has developed proprietary reagents and instruments that deliver accurate results in less than one hour, allowing for quick detection of dangerous water and foodborne pathogens. This technology enables clients to obtain quantitative data on contamination levels, thereby enhancing overall safety in food and water supplies.

Ar Diagnostic is a technology-based company dedicated to the analysis of levels of comfort and control of indoor air quality in buildings. Indoor environment must provide the adequate conditions for human comfort, free of public health risks or hazards and the conditions for productivity enhancement. In an ever demanding market economy, each sector as to respond to high standards of excellence and closely observe the emerging needs of the modern society. To invest in the analysis of comfort levels and indoor air quality, represents a valuable asset. This project was distinguished in 2004 with the “best business idea” award in the Ideas and Business Contest within Project FIVE promoted by IAPMEI with the support of the Portuguese Ministry of Economy.

Optomed Oy is a Finnish medical technology company that specializes in retinal imaging devices and solutions. The company focuses on developing, commercializing, and manufacturing handheld fundus cameras that facilitate the screening of various eye diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD). Optomed’s devices are designed to be user-friendly and accessible, making eye disease screenings available in diverse clinical settings worldwide. The company's products meet the international ISO 10940 fundus camera standards and are utilized by private clinics, public hospitals, and non-governmental organizations across major markets such as Europe, the USA, China, and India. In addition to its hardware offerings, Optomed also develops screening software for healthcare organizations. Headquartered in Oulu, Finland, Optomed maintains local offices in Shanghai, China, and Espoo, Finland.

MilliDrop Instruments SAS specializes in the design and development of cell culture machines utilizing millifluidics technology for bacteriological research and diagnostic applications. Founded in 2015 and based in Paris, France, the company offers advanced in vitro diagnostic machines that facilitate the incubation, analysis, and manipulation of samples, with volumes ranging from approximately 100 nanolitres to a few picolitres. Their innovative MilliDrop DIV instruments enable users to identify infectious agents and determine the appropriate antibiotic doses needed to effectively combat them, thereby minimizing therapeutic failures linked to improper antibiotic selection or excessive dosages. Additionally, MilliDrop's analyzers allow for the simultaneous study and cultivation of various cell cultures, as well as the sorting of phenotypes of interest and conducting serial dilutions, supporting microbiologists in their efforts to screen microbes for antimicrobial susceptibility testing.

Into.care is a mobile health collaboration platform that empowers medical staff by streamlining their workflows. The platform integrates patient records, telemetric data, and a decision support system, allowing for efficient management of healthcare routines. It facilitates basic patient administration, work planning, medication management, and reporting, enabling healthcare providers to focus on patient care rather than administrative tasks. By collecting and securely communicating data from connected healthcare devices, into.care aims to enhance operational efficiency and improve patient quality of life across all levels of healthcare organizations.

PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.